<b>Elon Musk</b> Launches Neuroscience Startup to Plug AI Into Your Brain

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-scientists2.jpg" NAME"Elon Musk Launches Neuroscience Startup to Plug AI Into Your Brain" ALT"Elon Musk Launches Neuroscience Startup to Plug AI Into Your Brain"March 28, 2017By Alex Keown, BioSpace.com Breaking…

Continue Reading<b>Elon Musk</b> Launches Neuroscience Startup to Plug AI Into Your Brain

While 3-Way Bids Go On, STADA Arzneimittel CEO's Car is Bugged, Received Photos of Himself in Personal or Private Biz Situations

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-merger.jpg" NAME"While 3-Way Bids Go On, Stada's CEO's Car is Bugged, Received Photos of Himself in Personal or Private Biz Situations" ALT"While 3-Way Bids Go On, Stada's CEO's Car…

Continue ReadingWhile 3-Way Bids Go On, STADA Arzneimittel CEO's Car is Bugged, Received Photos of Himself in Personal or Private Biz Situations

FDA Clears Massachusetts Biotech Tesaro's Ovarian Cancer PARP Inhibitor

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-fda.jpg" NAME"FDA Clears Massachusetts Biotech Tesaro's Ovarian Cancer PARP Inhibitor" ALT"FDA Clears Massachusetts Biotech Tesaro's Ovarian Cancer PARP Inhibitor"March 28, 2017By Alex Keown, BioSpace.com Breaking News Staff... Source: BioSpace

Continue ReadingFDA Clears Massachusetts Biotech Tesaro's Ovarian Cancer PARP Inhibitor

Never Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by $5 Billion

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-bristol-myers-squibb.jpg" NAME"Never Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by $5 Billion" ALT"Never Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by…

Continue ReadingNever Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by $5 Billion